金吾财讯 | 三生制药(01530)股价逆市走低，截至发稿，报24港元，跌5.44%，成交额10.82亿港元。国信证券表示，基于公司国内药品销售业务存在一定压力，该机构小幅下调2026-27年的盈利预测，并新增2028年盈利预测。预计2026-28年公司归母净利润为24.5/26.6/27.9亿元（26-27年前值为28.8/32.1），同比增长-71.2%/8.9%/4.7%，对应当前股价PE=24.6/22.5/21.5x。公司的707快速开启全球3期多中心临床，有望成为重磅炸弹，维持“优于大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.